Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reiterated its Buy rating for Clearside Biomedical (NASDAQ:CLSD) and maintained a price target of $6.
October 14, 2024 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for Clearside Biomedical and maintained a price target of $6, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a specific price target by Chardan Capital suggests positive sentiment and expected growth for Clearside Biomedical. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100